Cynosure Inc. (CYNO) Shares Sold by Fisher Asset Management LLC
Fisher Asset Management LLC lowered its position in Cynosure Inc. (NASDAQ:CYNO) by 23.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 73,253 shares of the company’s stock after selling 22,917 shares during the period. Fisher Asset Management LLC owned approximately 0.31% of Cynosure worth $3,732,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of CYNO. Advisory Services Network LLC increased its stake in Cynosure by 18.2% in the third quarter. Advisory Services Network LLC now owns 15,410 shares of the company’s stock worth $785,000 after buying an additional 2,370 shares during the period. New England Research & Management Inc. acquired a new stake in Cynosure during the third quarter worth about $309,000. Macquarie Group Ltd. acquired a new stake in Cynosure during the second quarter worth about $1,581,000. Mason Street Advisors LLC acquired a new stake in Cynosure during the second quarter worth about $224,000. Finally, Aristotle Capital Boston LLC increased its stake in Cynosure by 2.7% in the second quarter. Aristotle Capital Boston LLC now owns 75,754 shares of the company’s stock worth $3,685,000 after buying an additional 1,965 shares during the period. 99.89% of the stock is owned by hedge funds and other institutional investors.
Cynosure Inc. (NASDAQ:CYNO) traded down 1.20% during trading on Wednesday, hitting $45.35. The stock had a trading volume of 297,486 shares. The company’s 50-day moving average is $45.39 and its 200 day moving average is $49.43. The firm has a market cap of $1.08 billion, a PE ratio of 51.24 and a beta of 1.71. Cynosure Inc. has a 52 week low of $32.90 and a 52 week high of $55.94.
Cynosure (NASDAQ:CYNO) last announced its quarterly earnings data on Tuesday, October 25th. The company reported $0.29 EPS for the quarter, topping the Zacks’ consensus estimate of $0.28 by $0.01. Cynosure had a return on equity of 6.82% and a net margin of 4.97%. The firm earned $106.40 million during the quarter, compared to analyst estimates of $101.11 million. During the same period last year, the company posted $0.21 EPS. The business’s quarterly revenue was up 35.7% compared to the same quarter last year. Equities analysts expect that Cynosure Inc. will post $1.28 EPS for the current fiscal year.
A number of analysts recently issued reports on the stock. TheStreet downgraded shares of Cynosure from a “buy” rating to a “hold” rating in a research report on Wednesday, November 16th. Northcoast Research reaffirmed a “buy” rating on shares of Cynosure in a research report on Monday, November 14th. Aegis began coverage on shares of Cynosure in a research report on Wednesday, November 2nd. They issued a “buy” rating and a $60.00 price objective for the company. Leerink Swann reaffirmed an “outperform” rating and issued a $60.00 price objective (down previously from $63.00) on shares of Cynosure in a research report on Friday, October 28th. Finally, Zacks Investment Research downgraded shares of Cynosure from a “hold” rating to a “sell” rating in a research report on Wednesday, October 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $60.43.
In other news, VP Douglas J. Delaney sold 7,875 shares of Cynosure stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $45.00, for a total transaction of $354,375.00. Following the completion of the sale, the vice president now directly owns 5,833 shares in the company, valued at approximately $262,485. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Chairman Michael R. Davin sold 16,284 shares of Cynosure stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $45.00, for a total value of $732,780.00. Following the sale, the chairman now owns 4,222 shares of the company’s stock, valued at $189,990. The disclosure for this sale can be found here. Company insiders own 2.90% of the company’s stock.
Cynosure Inc (Cynosure) develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health.
Receive News & Stock Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related stocks with our FREE daily email newsletter.